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ABSTRACT 
Oesophageal Atresia (OA) with or without Tracheoesophageal Fistula (TOF) are rare 
anatomical congenital malformations whose cause is unknown in over 90% of patients. A 
genetic background is suggested and among the reported genetic defects are Copy Number 
Variations (CNVs). We hypothesized that CNVs contribute to OA/TOF development. 
Quantifying their prevalence could aid in genetic diagnosis and clinical care strategies. 
Therefore, we profiled 375 patients in a combined Dutch, American and German cohort via 
genomic micro-array and compared the CNV-profiles with their unaffected parents and 
published control cohorts. We identified 167 rare CNVs containing genes. (frequency < 
0.0005 in our in-house cohort)  Eight rare CNVs – in 6 patients - were de novo, including one 
CNV previously associated with oesophageal disease. (hg19 
chr7:g.(143820444_143839360)_(159119486_159138663)del) 1.55% of isolated OA/TOF 
patients and 1.62% of patients with additional congenital anomalies had de novo CNVs. 
Furthermore, three (15q13.3, 16p13.3 and 22q11.2) susceptibility loci were identified based 
on their overlap with known OA/TOF associated CNV syndromes and overlap with loci in 
published CNV association case-control studies in developmental delay. Our study suggests 
that CNVs contribute to OA/TOF development. In addition to the identified likely deleterious 
de novo CNVs, we detected 167 rare CNVs. While not directly disease causing, these CNVs 
might be of interest, as they can act as a modifier in a multiple hit model, or as the second hit 
in a recessive condition. 
INTRODUCTION 
Oesophageal Atresia (OA) with or without Tracheoesophageal fistula (TOF) are anatomical 
congenital malformations believed to be caused by multiple genetic and environmental 
factors.1 With a prevalence of 2-3 in 10,000 live births, OA/TOF is a rare foregut-related 
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anomaly.2 Around 50% of affected individuals present with additional congenital anatomical 
malformations.3 Often -but not exclusively- these belong to the VATER/VACTERL 
association spectrum of vertebral defects (V), anorectal malformations (A), cardiac defects 
(C), tracheoesophageal fistula with or without oesophageal atresia (TE ), renal anomalies (R) 
and radial limb defects (L).4,5  
A confirmed genetic syndrome or a chromosomal anomaly -including aneuploidies as trisomy 
13, 18 and 21- can be identified in 6-10% of patients6 and there is a strong suspicion that 
genetic factors are involved in the remainder. A genetic background is further suggested by 
reports of families with multiple affected individuals, higher concordance rates in 
monozygotic twins compared to dizygotic twins7, higher recurrence risk for siblings and 
children of affected individuals, and OA/TOF as a component features in numerous known 
chromosomal aberrations and monogenic syndromes.8 Reports describing disease causing 
Copy Number Variations (CNVs) in patients with OA/TOF are rare.9,10 In addition to their 
well-established role in the development of congenital anatomical malformations in general11, 
CNVs contribute to disease aetiology in several genetic syndromes. These include those 
having OA/TOF as part of their phenotypic spectrum such as Feingold syndrome12, 22q11 
deletion syndrome13, CHARGE syndrome14 and mandibulofacial dysostosis.15 Furthermore, 
de novo disease causing CNVs have been described in patients with non-syndromic OA/TOF 
and the VACTERL association.16  
To determine the contribution of CNVs in OA/TOF aetiology, we profiled 375 Dutch, 
German and American OA/TOF patients in a comprehensive multiplatform array. We suggest 
that genomic de novo and rare overlapping CNVs contribute to isolated and non-isolated 
OA/TOF. These CNVs would harbour one or more disease-related genes or phenotype-
modifying factors. We describe the variation detected in our large cohort. This study enabled 
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us to identify several rare overlapping CNVs and non-overlapping de novo CNVs which 
potentially provide new insights into the biological pathways and disease mechanisms 
involved in the development of OA/TOF.  
METHODS 
Study design 
We assessed the CNVs according to the consensus statement for chromosomal micro-array 
analysis described by Miller and co-workers.17 Our study design was based on the 
assumptions that CNVs are most likely to contributte to the abnormal phenotype in congenital 
anomalies if (I) a CNV is absent in large cohorts of unaffected individuals, (II) is absent in the 
unaffected parents of the affected individual and/or (III) is absent or has a population 
frequency below or comparable to the disease frequency and (IV) if it targets relevant genes 
or non-coding RNAs. Recurrence of loci affected by de novo CNVs in single cases could 
indicate loci harbouring genes mutated or otherwise affected in larger disease cohorts. A 
detailed description of the study design is given in the supplementary methods. 
 
Patient cohort 
This study was approved by the institutional ethics committee of each participating centre, 
and was conducted in accordance with the principles of the Declaration of Helsinki. Patients 
with OA/TOF (isolated or non-isolated) were identified from the medical records. All patient 
records were reviewed by the treating physicians or geneticists of each participating centre. 
After retrieval of parental informed consent, blood was drawn from a total of 375 patients and 
their parents, comprising 239 patients from the Erasmus MC- Sophia, 28 from the Baylor 
College of Medicine, and 108 from a German multi-centre study regarding the genetic and 
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environmental cause of OA/TOF (“The genetic risk for oesophageal atresia consortium 
[GREAT-consortium]”).  
Micro-array analysis 
High-resolution analyses were performed using single-nucleotide polymorphism (SNP) 
microarrays (Illumina Inc., San Diego, CA, USA and Affymetrix Inc. Santa Clara, CA, USA) 
and CGH oligonucleotide-based arrays (Agilent Inc., San Diego, CA, USA) using standard 
protocols. SNP data (Log-R ratio, B-Allele Frequency) were visualized to identify potential 
CNVs via Biodiscovery Nexus CN7.5. (Biodiscovery Inc., Hawthorne, CA, USA) and the 
GenomeStudio genotyping module (v1.9.4, www.illumnia.com). A detailed description of 
chip types, normalized output generation and analysis settings is provided in the 
supplementary methods. CNVs were - prior to validation studies- first filtered and prioritized 
based on size, probe content, quality, frequency in reference cohorts, gene content and 
frequency in our OA cohorts. All CNVs passing the filter criteria were evaluated manually in 
modified version (i.e. excluding BAC arrays and small InDels) of the database of genomic 
variation (DGV, http://dgv.tcag.ca/dgv/app/home), ISCA 
(http://dbsearch.clinicalgenome.org/search/), ClinGen (https://www.clinicalgenome.org/data-
sharing/clinvar/) and DECIPHER. (http://decipher.sanger.ac.uk)  We classified CNVs to be 
rare if they were absent or present once in our in-house cohort of unaffected individuals. 
(n=3235 individuals) We searched for overlap in large CNV cohorts of control individuals 
published by Cooper et al.18, Coe et al.19 and Kaminsky et al.20 We also evaluated the CNVs 
significantly different in these studies between patients and controls. To confirm the putative 
de novo and putative deleterious CNVs, patient and parental DNA were tested with either 
additional SNP array, Real Time Quantitative PCR, Fluorescence In Situ Hybridization 
(FISH) and/or Multiplex Amplicon Quantification (MAQ) (Multiplicon N.V., Gent, 
Belgium). A detailed description of these methods is given in the supplementary methods. All 
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rare CNVs are listed in supplementary table 3 and are deposited in the ClinVar database 
(http://www.ncbi.nlm.nih.gov/clinvar/) using the submission name “CNV study in EA/TEF” 
and using the exact identifiers as described in this manuscript.  
RESULTS 
Patient cohort 
In this study a total of 375 OA/TOF patients were screened for their respective CNV profile. 
129 of these patients presented with OA/TOF as an isolated defect (34.4%). Of the non-
isolated patients with OA/TOF, 142 met the afore mentioned criteria for the clinical diagnosis 
of VACTERL (37.8%).  
Micro-array analysis 
Screening the respective cohorts (see figure 1) with high-resolution oligonucleotide and SNP 
microarrays led to the identification of 169 CNV. (gene-rich –containing genes- (n=167) and 
gene-poor (n=2)) These, will be addressed as rare CNVs in the remainder of the manuscript. 
Their size distributions are depicted in figure 2, genomic locations, evaluation of presence in 
control databases and classifications are given in supplementary table 2. Almost all of the rare 
CNVs were widely distributed over the genome. However, our analysis yielded a total of 12 
loci which were affected by a rare CNV more than once and were present in more than one 
patient (see supplementary table 1 for the regions and phenotypes of patients with rare CNVs 
and overlapping loci). Inheritance was determined using secondary technology as MAQ-assay 
or qPCR in 17 out of 74 CNVs either suspected to be de novo CNVs after trio analysis using 
micro-array or based on suspected deleteriousness in single patient micro-array analysis. (see 
supplementary figure 1)  
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Eight out of these 74 rare CNVs selected for further investigation (10.8 %) – in 6 patients 
(1.6%) - were confirmed to be de novo. (see table 1, and figure 3 and 4 for examples) 
Additionally, one locus harboured a 15q11 de novo CNV deletion (hg19 
chr15:g.(?_19339852-20216728_?), common in the database of genomic variants. (see 
supplementary figure 1) All but one de novo CNVs were non-recurrent and non-overlapping 
in our cohort. For four patients DNA of only one parent was available, thus preventing 
determination of inheritance of the rare CNV in the missing parent. Haplotype analysis of the 
locus could confirm that the haplotype present in the patient was not the haplotype of the 
available parent in three out of four CNVs. In table 1 the phenotypes of patients with 
confirmed de novo CNVs detected in this study and in table 2 the de novo CNVs described in 
literature are shown. Most de novo CNVs described here and in literature are non-recurrent 
i.e. there are no overlapping loci. The only recurrent affected de novo locus is 7q35q36 (see 
figure 3). One de novo CNV (16p13.3 duplication, see table 1) overlapped two inherited 
16p13.3 duplications. (see table 3) We classified the rare CNVs as benign (45), uncertain-
likely benign (106) and 7 as uncertain. Interestingly, we could classify nine CNVs as 
uncertain-likely pathogenic and two as pathogenic. These putative deleterious CNVs seen in 
10 patients (2,6%) are depicted in table 3. Two of these were confirmed to be de novo, four 
were inherited from parents without oesophageal atresia and for four CNVs the inheritance 
pattern is not known. 
Discussion 
We hypothesized that both de novo and rare overlapping CNVs could predispose to -or 
modify the phenotype of- OA/TOF patients. These disease associated CNVs should be below 
or in the same frequency range as OA/TOF disease prevalence. We identified 169 of these 
rare CNVs including eight de novo CNVs (non-overlapping) and twelve loci with overlapping 
8 
 
rare gene-rich CNVs. Six patients in our cohort had rare CNVs confirmed to be de novo. The 
distribution of these de novo CNVs is comparable between isolated and non-isolated OA/TOF 
patients: two patients with isolated OA/TOF had one de novo CNV each. (0.53% of total 
patient cohort; 1.55% of patients with isolated OA/TOF) Two patients with non-isolated 
OA/TOF had one de novo CNV each and two had two de novo CNVs. (1.06% in total cohort; 
1.62 % of non-isolated OA patients) All de novo CNVs were non-recurrent in our cohort. 
However, there is overlap with structural chromosomal anomalies previously described in 
OA/TOF.29 For instance, the chromosomal anomaly described by Jackson and co-workers 
(46,XX,-13,+der(18)t(13;18)(q12;p11.2)30 overlaps with the 13q12 deletion detected in 
patient SKZ_1662. Genes in the deleted region may contribute to the OA/TOF aetiology. 
Unfortunately, little is known about the genes within the region of overlap. 
Based on the assumption that a CNV has a high likelihood of being pathogenic if it is not 
present in cohorts of unaffected individuals as well as absent in both unaffected parents -we 
could classify two out of eight de novo CNVs as (likely-) pathogenic i.e. those at the loci 
16p13.11 and at 7q35q36. No tracheoesophageal mouse phenotypes are described for any of 
the genes affected by de novo CNVs except for two genes in the 7q35q36 locus - Shh and 
Slc4a2. Shh knockout mice have numerous malformations including tracheoesophageal 
fistula, a small stomach, reduction of oesophageal tissue fused with the trachea, anal atresia 
and duodenal stenosis.31 Slc4a2 knockout mice develop hyperkeratosis in oesophageal and 
stomach epithelium.32 However, the 7q35q36  deletion is very large – containing many genes 
– other genes could also contribute to the abnormal phenotype seen in this patient. The 
remaining six remaining de novo CNVs affected loci present in large CNV control cohorts. 
(see supplementary table 2) The total number of patients with rare de novo CNVs is six out of 
375 (1.6%). The de novo rate of 1.6% is slightly elevated compared to the de novo rate per 
genome/generation described by Itsara and co-workers.33,34 They estimate a de novo rate of 
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large CNVs to be 1.2%. However, these include more prevalent CNVs and not a selected 
subset. In other diseases, de novo CNVs have a much higher impact e.g. Congenital 
Diaphragmatic Hernia35 or intellectual disability.36 The de novo CNVs seen in this study are 
non-overlapping and some of them do not affect genes with clear association to the 
abnormalities seen in patients. Therefore, the significance of some of these de novo CNVs to 
the disease remain uncertain.  
For instance, one de novo 13q11.2 deletion involves a female patient (SKZ_1662) born out of 
a twin pregnancy. Her twin died in utero. Unfortunately, there was neither patient material nor 
information regarding the observed congenital anomalies or zygosity status of this foetus 
available. The female index patient had OA/TOF, tracheal stenosis, a sacral abnormality and 
her left kidney was abnormally positioned in the midline. Within the deleted 13q12.11 region 
one transcribed mRNA (AK054845) and one lncRNA (LINC00540) are located. No biological 
role or putative function has been described for these RNA’s, so far. However, one family – 
with congenital fibrosis of extra-ocular muscles-was reported having a translocation 
breakpoint (t(2;13)(q37.3;q12.11) in this region. Mice fgf9 knockouts showed a wide variety 
of abnormalities, including developmental problems of the skeletal, respiratory and the 
gastrointestinal system.37 The 13q12.11 de novo deletion observed in our patient is 
approximately 500kb of FGF9 suggesting that a regulatory region of FGF9 might be affected 
by the deletion. Female patient SKZ_1307 has a de novo duplication affecting a long non-
coding RNA, LINC00114, on chromosome 21 (chr21:40100880-40154748) confirmed with 
MAQ assay. LINC00114 is located between V-Ets Avian Erythroblastosis Virus E26 
Oncogene Homolog (ERG) and V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 
2 (ETS2) within the Down syndrome critical region.19 The girl has OA/TOF and anal stenosis 
as main additional feature. She does not have distinct Down syndrome facial features or 
mental retardation. The ERG and ETS2 transcription factors might be regulated by the 
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LINC00114. Unfortunately, no mouse orthologue for this region exists.38 ERG and ETS2 are 
implicated as secondary hits -after an initial truncating GATA1 mutation- in the development 
of neonatal transient myeloproliferative disease preceding myeloid leukaemia seen Down 
syndrome patients.39 Patients with Down syndrome have a higher prevalence of several 
gastro-intestinal defects, including OA/TOF.40 This is the first de novo duplication involving 
only one gene or long non-coding RNA in a patient with OA. Further investigation of the role 
of LINC00114 in OA/TOF and Down syndrome patients with intestinal atresia is warranted. 
The identified de novo duplication on chromosome 3p26.1 in female patient 
DE12OSOUKBD100206 with OA and tracheomalacia comprises LMCD1 encoding LIM and 
cysteine-rich domains protein 1, which acts as a transcriptional cofactor restricting the 
function of GATA641, a protein playing an important role in endodermal differentiation.42 
Moreover, GATA6 expression has previously been reported to be elevated during the 
development and progression of Barrett’s oesophagus in squamous epithelial cells.43 Hence, 
the present finding of a de novo duplication comprising LMCD1 in a patient with OA/TOF is 
suggestive of its pathogenic involvement in the development of OA/TOF. The importance and 
biological impact of the other de novo deletions/duplications is uncertain.  
Of note, one de novo loss - a common polymorphism- was detected: hg19 
chr15:g.(?_19339852)_(20216728_?)del. This CNV was detected during visual inspection of 
patient and parental SNP-arrays for inheritance of other CNVs. This 15q11.2 polymorphism 
overlapped with a previously described genetic loss implicated in patients with congenital 
anatomical malformations - including OA/TOF.44 This region is deleted in three more 
oesophageal atresia patients in our cohort.45 However, its` high frequency in unaffected 
individuals and repetitive nature (e.g. many LINE, SINE and other repetitive elements) 
hampers interpretation and classification of this CNV.  
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Overlapping rare CNVs 
Rare CNVs are proposed to arise after replication errors 11 and have such a low population 
frequency that either they have arisen recently and have no biological meaning or -are 
somehow detrimental and are virtually extinct from the population. Interpretation of these 
CNVs is difficult. For instance, they can be ancestry specific.46 Inheritance of a single CNV 
from a healthy parent is generally a characteristic of a benign CNV. However, absence of 
distinct abnormalities in parents carrying the same rare CNV could for instance be explained 
by a subclinical phenotype in these parents, variable gene expressivity, incomplete 
penetrance, skewed X-inactivation and/or mutations elsewhere in the genome.11 Reduced 
penetrance or variable expressivity of CNVs has been described in patients with OA/TOF. For 
instance, Faguer described differences in expression of a microduplication47 in patients with 
the same microduplication, a father with bilateral vesico-ureteric reflux and renal 
hypodysplasia and his child with left multicystic dysplastic kidney with megaureter, vesico-
ureteric reflux, bladder diverticulae and OA/TOF. Both patients have the same duplication on 
chromosomal locus 17q12 which includes HNF1B, a gene mutated in one fifth of patients 
with dysplastic kidneys.47 
The best way to see if a CNV is associated to a disease is to do a formal burden test.48 We are 
not able to do this test due to the limited number of patients in a rare disease, and due to 
technical limitations (use of different array chips). More details are given in the 
supplementary discussion. However, we can look for overlap with CNVs described 
previously in CNV burden studies and inspect if OA/TOF has been described in patients with 
such a CNV. Therefore, we used the CNV burden studies published by Cooper et al.18, Coe et 
al.19 and Kaminsky et al.20 as a proxy (Developmental delay vs controls) after filtering all 
common CNVs. Here, they did use sufficient numbers of patients and controls and find an 
enrichment of a small number of loci in this heterogeneous patient population of 
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developmental delay and/or congenital anomalies. Only the 16p13.3 duplication enriched in 
patients in these studies was recurrent in our cohort. The largest of the three duplications – 
seen in patient SKZ_2111 - was de novo. The two other paternally inherited 16p13.3 
duplications were present in patient SKZ_1988 and SKZ_1150. Duplications of this region-
between the NOMO1 and XYLT1 gene- have been described previously in patients with 
various phenotypical anomalies, including the OA/TOF associated congenital anomalies anal 
and cardiac malformations.49 None of the other overlapping rare CNVs found in our cohort 
(see supplementary table 1) was enriched in the developmental delay study.  
Non-recurrent CNVs seen in our cohort did overlap enriched CNVs in these burden studies or 
with CNVs published in patient databases. For instance, the 15q13.3 deletion seen in male 
patient SKZ_0856 overlaps with a known deleterious CNV18 seen in patients with a highly 
variable phenotype which include mild to moderate intellectual disability and variable 
dysmorphic features.50 Other CNVs with overlap in our study are the gain involving FAT1 on 
4q35.2 in patient SKZ_1248, the 6p22 deletion in patient SKZ_185618 , the 2q13 duplication 
seen in patient DE61OSOUKBD10019719 and 22q11 gain18  seen in female patient 
SKZ_1780 Interestingly, two additional published EA/TEF patients have a 22q11 duplication 
overlapping the one seen in patient SKZ_1780.  The DECIPHER  database contains an 
inherited gain (chr22:19095778-19928090) described in patient 3771 – with TOF, upper 
respiratory tract abnormality, coloboma, hearing impairment, horseshoe kidney and a right 
aortic arch with mirror image branching. The second is a paternally inherited duplication in a 
patient with OA/TOF and ventricular septal defect.51  
Rare CNVs could be determinants in secondary phenotypical anomalies and/or serve as a  
second ‘hit’ tilting the balance from normal to abnormal development. Duplications might be 
rescue mechanisms in which a normal copy is duplicated to balance out a copy affected by a 
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mutation, resulting in increased gene expression or deletions might worsen an otherwise less 
severe condition. OA/TOF is a variable feature in several single gene disorders. Perhaps the 
presence of these disorders is higher than currently diagnosed. Recognizing the phenotypical 
spectra might be hampered by uncharacteristic phenotypical features in patients carrying both 
a modifying rare CNV and a gene mutation. It might be worthwhile to screen large OA/TOF 
patient cohorts retrospectively for mutations in known disease genes. Unfortunately, due to 
the large number of genes and non-recurrence of de novo CNVs, it is not feasible to establish 
their contribution to OA/TOF disease etiology.  Moreover, the lack of availability of OA/TOF 
patient samples and heterogeneity of the rare CNVs hamper formal burden analysis to prove 
association. However, the de novo nature of CNVs in patients and absence of overlapping 
CNVs in a large control cohorts is interesting. Perhaps future CNV profiling or sequencing 
studies will detect deleterious variation in overlapping genes paving the way for further single 
gene based functional studies.   
Concluding remarks 
We hypothesized that de novo and overlapping rare recurrent CNVs could contribute to the 
disturbed development of the oesophagus. Quantifying CNV prevalence and identity could 
aid in genetic diagnosis and clinical care selection. We found several de novo and rare 
overlapping CNVs. Our screening indicated that the prevalence of de novo CNVs on OA/TOF 
patient population is 1.6%.  Based on their function, overlap with loci in published case-
control studies, known CNV syndromes and foregut phenotypes in animal models we suggest 
SHH and SLC4A2 as contributing factors in a contiguous gene deletion to OA/TOF disease 
aetiology and 15q13.3, 16p13.3 and 22q11.2 as candidate susceptibility loci. With aneuploidy 
and structural chromosomal anomalies (~4%) and single base pair mutations (~6 %) now 
CNVs (~1-2 %) totals the genetic contribution of OA/TOF disease aetiology to about ~11-
12%. Mutation screening using candidate gene approaches, whole exome or whole genome 
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sequencing as well as sequencing large patient-parent cohorts – both prospectively and 
retrospectively- will likely reveal known and new pathogenic DNA variations, increasing the 
contribution of genetics and our knowledge of OA/TOF disease aetiology.  
Acknowledgments  
We thank all families and patients for their cooperation, and the self-help organizations from 
Germany “KEKS e.V.” and the Netherlands “VOKS” for their assistance with recruitment. 
The authors thank David Alexander for editorial support. Erwin Brosens was funded by the 
Sophia Foundations for Scientific Research, projects SSWO- 493 and SWOO13-09. Heiko 
Reutter and Johannes Schumacher are funded by a grant of the Else Kröner-Fresenius-
Stiftung (EKFS) (funding code 2014_A14). A full list of centres who contributed to the 
generation of the Decipher community data is available from http://decipher.sanger.ac.uk and 
via email from decipher@sanger.ac.uk. Funding for the project was provided by the 
Wellcome Trust.” 
 
Conflict of Interest 
Authors do not have any potential conflicts (financial, professional, or personal) relevant to 
the manuscript to disclose.   
15 
 
References 
 
1. Felix JF, de Jong EM, Torfs CP, de Klein A, Rottier RJ, Tibboel D: Genetic and 
environmental factors in the etiology of esophageal atresia and/or tracheoesophageal 
fistula: an overview of the current concepts. Birth defects research Part A, Clinical 
and molecular teratology 2009; 85: 747-754. 
2. Pedersen RN, Calzolari E, Husby S, Garne E: Oesophageal atresia: prevalence, 
prenatal diagnosis and associated anomalies in 23 European regions. Archives of 
disease in childhood 2012; 97: 227-232. 
3. Genevieve D, de Pontual L, Amiel J, Sarnacki S, Lyonnet S: An overview of isolated 
and syndromic oesophageal atresia. Clinical genetics 2007; 71: 392-399. 
4. Quan L, Smith DW: The VATER association. Vertebral defects, Anal atresia, T-E 
fistula with esophageal atresia, Radial and Renal dysplasia: a spectrum of associated 
defects. The Journal of pediatrics 1973; 82: 104-107. 
5. Temtamy SA, Miller JD: Extending the scope of the VATER association: definition of 
the VATER syndrome. The Journal of pediatrics 1974; 85: 345-349. 
6. Genevieve D, de Pontual L, Amiel J, Lyonnet S: Genetic factors in isolated and 
syndromic esophageal atresia. J Pediatr Gastroenterol Nutr 2011; 52 Suppl 1: S6-8. 
7. Schulz AC, Bartels E, Stressig R et al: Nine new twin pairs with esophageal atresia: a 
review of the literature and performance of a twin study of the disorder. Birth defects 
research Part A, Clinical and molecular teratology 2012; 94: 182-186. 
16 
 
8. Brosens E, Ploeg M, van Bever Y et al: Clinical and etiological heterogeneity in 
patients with tracheo-esophageal malformations and associated anomalies. European 
journal of medical genetics 2014; 57: 440-452. 
9. Reutter H, Ludwig M: VATER/VACTERL Association: Evidence for the Role of 
Genetic Factors. Molecular syndromology 2013; 4: 16-19. 
10. Bednarczyk D, Sasiadek MM, Smigiel R: Chromosome Aberrations And Gene 
Mutations In Patients With Esophageal Atresia. J Pediatr Gastroenterol Nutr 2013. 
11. Stankiewicz P, Lupski JR: Structural variation in the human genome and its role in 
disease. Annual review of medicine 2010; 61: 437-455. 
12. Cognet M, Nougayrede A, Malan V et al: Dissection of the MYCN locus in Feingold 
syndrome and isolated oesophageal atresia. European journal of human genetics : 
EJHG 2011; 19: 602-606. 
13. Digilio MC, McDonald-McGinn DM, Heike C et al: Three patients with oculo-
auriculo-vertebral spectrum and microdeletion 22q11.2. American journal of medical 
genetics Part A 2009; 149A: 2860-2864. 
14. Corsten-Janssen N, Saitta SC, Hoefsloot LH et al: More Clinical Overlap between 
22q11.2 Deletion Syndrome and CHARGE Syndrome than Often Anticipated. 
Molecular syndromology 2013; 4: 235-245. 
15. Gordon CT, Petit F, Oufadem M et al: EFTUD2 haploinsufficiency leads to 
syndromic oesophageal atresia. J Med Genet 2012; 49: 737-746. 
17 
 
16. Brosens E, Eussen H, van Bever Y et al: VACTERL Association Etiology: The 
Impact of de novo and Rare Copy Number Variations. Molecular syndromology 2013; 
4: 20-26. 
17. Miller DT, Adam MP, Aradhya S et al: Consensus statement: chromosomal 
microarray is a first-tier clinical diagnostic test for individuals with developmental 
disabilities or congenital anomalies. Am J Hum Genet 2010; 86: 749-764. 
18. Cooper GM, Coe BP, Girirajan S et al: A copy number variation morbidity map of 
developmental delay. Nat Genet 2011; 43: 838-846. 
19. Coe BP, Witherspoon K, Rosenfeld JA-O et al: Refining analyses of copy number 
variation identifies specific genes associated with developmental delay. 
20. Kaminsky EB, Kaul V, Paschall J et al: An evidence-based approach to establish the 
functional and clinical significance of copy number variants in intellectual and 
developmental disabilities. Genetics in medicine : official journal of the American 
College of Medical Genetics 2011; 13: 777-784. 
21. Hilger A, Schramm C, Pennimpede T et al: De novo microduplications at 1q41, 
2q37.3, and 8q24.3 in patients with VATER/VACTERL association. European 
journal of human genetics : EJHG 2013; 21: 1377-1382. 
22. van Binsbergen E, Ellis RJ, Abdelmalik N et al: A fetus with de novo 2q33.2q35 
deletion including MAP2 with brain anomalies, esophageal atresia, and laryngeal 
stenosis. American journal of medical genetics Part A 2014; 164a: 194-198. 
23. Arrington CB, Patel A, Bacino CA, Bowles NE: Haploinsufficiency of the LIM 
domain containing preferred translocation partner in lipoma (LPP) gene in patients 
18 
 
with tetralogy of Fallot and VACTERL association. American journal of medical 
genetics Part A 2010; 152a: 2919-2923. 
24. Zen PR, Riegel M, Rosa RF et al: Esophageal stenosis in a child presenting a de novo 
7q terminal deletion. European journal of medical genetics 2010; 53: 333-336. 
25. Speleman F, Van Roy N, Wiegant J et al: Detection of subtle reciprocal translocations 
by fluorescence in situ hybridization. Clinical genetics 1992; 41: 169-174. 
26. Ferreira de Almeida T, Bertola DR: Microdeletion 11q13.1.q13.2 in a patient 
presenting with developmental delay, facial dysmorphism, and esophageal atresia: 
possible role of the GSTP1 gene in esophagus malformation. Birth defects research 
Part A, Clinical and molecular teratology 2013; 97: 463-466. 
27. Smigiel R, Marcelis C, Patkowski D et al: Oesophageal atresia with 
tracheoesophageal fistula and anal atresia in a patient with a de novo microduplication 
in 17q12. European journal of medical genetics 2014; 57: 40-43. 
28. Solomon BD, Pineda-Alvarez DE, Hadley DW et al: De novo deletion of chromosome 
20q13.33 in a patient with tracheo-esophageal fistula, cardiac defects and 
genitourinary anomalies implicates GTPBP5 as a candidate gene. Birth defects 
research Part A, Clinical and molecular teratology 2011; 91: 862-865. 
29. Felix JF, Tibboel D, de Klein A: Chromosomal anomalies in the aetiology of 
oesophageal atresia and tracheo-oesophageal fistula. European journal of medical 
genetics 2007; 50: 163-175. 
30. Jackson J, Robson L, Meagher S, Watson G, Smith A: How accurate does rapid fetal 
karyotyping need to be? Case of unbalanced t(13;18). Prenat Diagn 1993; 13: 767-
770. 
19 
 
31. Miller LA, Wert SE, Clark JC, Xu Y, Perl AK, Whitsett JA: Role of Sonic hedgehog 
in patterning of tracheal-bronchial cartilage and the peripheral lung. Dev Dyn 2004; 
231: 57-71. 
32. Gawenis LR, Ledoussal C, Judd LM et al: Mice with a targeted disruption of the AE2 
Cl-/HCO3- exchanger are achlorhydric. The Journal of biological chemistry 2004; 
279: 30531-30539. 
33. Itsara A, Wu H, Smith JD et al: De novo rates and selection of large copy number 
variation. Genome research 2010; 20: 1469-1481. 
34. Itsara A, Cooper GM, Baker C et al: Population analysis of large copy number 
variants and hotspots of human genetic disease. Am J Hum Genet 2009; 84: 148-161. 
35. Wat MJ, Veenma D, Hogue J et al: Genomic alterations that contribute to the 
development of isolated and non-isolated congenital diaphragmatic hernia. J Med 
Genet 2011; 48: 299-307. 
36. Hehir-Kwa JY, Rodriguez-Santiago B, Vissers LE et al: De novo copy number 
variants associated with intellectual disability have a paternal origin and age bias. J 
Med Genet 2011; 48: 776-778. 
37. Harada M, Murakami H, Okawa A et al: FGF9 monomer-dimer equilibrium regulates 
extracellular matrix affinity and tissue diffusion. Nat Genet 2009; 41: 289-298. 
38. Owczarek CM, Portbury KJ, Hardy MP et al: Detailed mapping of the ERG-ETS2 
interval of human chromosome 21 and comparison with the region of conserved 
synteny on mouse chromosome 16. Gene 2004; 324: 65-77. 
20 
 
39. Gruber TA, Downing JR: The biology of pediatric acute megakaryoblastic leukemia. 
Blood 2015; 126: 943-949. 
40. Freeman SB, Torfs CP, Romitti PA et al: Congenital gastrointestinal defects in Down 
syndrome: a report from the Atlanta and National Down Syndrome Projects. Clinical 
genetics 2009; 75: 180-184. 
41. Rath N, Wang Z Fau - Lu MM, Lu Mm Fau - Morrisey EE, Morrisey EE: 
LMCD1/Dyxin is a novel transcriptional cofactor that restricts GATA6 function by 
inhibiting DNA binding. 
42. Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5, and -6. 
Ubiquitously expressed regulators of tissue-specific gene expression. 
43. Pavlov K, Honing J, Meijer C et al: GATA6 expression in Barrett's oesophagus and 
oesophageal adenocarcinoma. 
44. Wong D, Johnson SM, Young D, Iwamoto L, Sood S, Slavin TP: Expanding the BP1-
BP2 15q11.2 Microdeletion Phenotype: Tracheoesophageal Fistula and Congenital 
Cataracts. Case Rep Genet 2013; 2013: 801094. 
45. Brosens E, Brouwer RWW, Brands T et al: Whole-exome mutation and CNV analysis 
in familial esophageal atresia manuscript in preparation 2014. 
46. Oei L, Hsu YH, Styrkarsdottir U et al: A genome-wide copy number association study 
of osteoporotic fractures points to the 6p25.1 locus. J Med Genet 2013. 
47. Faguer S, Chassaing N, Bandin F et al: A 17q12 chromosomal duplication associated 
with renal disease and esophageal atresia. European journal of medical genetics 2011; 
54: e437-440. 
21 
 
48. Barnes C, Plagnol V, Fitzgerald T et al: A robust statistical method for case-control 
association testing with copy number variation. Nat Genet 2008; 40: 1245-1252. 
49. Nagamani SC, Erez A, Bader P et al: Phenotypic manifestations of copy number 
variation in chromosome 16p13.11. European journal of human genetics : EJHG 
2011; 19: 280-286. 
50. van Bon BW, Mefford Hc Fau - Menten B, Menten B Fau - Koolen DA et al: Further 
delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum 
varying from non-pathogenic to a severe outcome. 
51. Puvabanditsin S, Garrow E, February M, Yen E, Mehta R: ESOPHAGEAL ATRESIA 
WITH RECURRENT TRACHEOESOPHAGEAL FISTULAS AND 
MICRODUPLICATION 22q11.23. Genetic counseling (Geneva, Switzerland) 2015; 
26: 313-320.  
22 
 
Figure and table legends 
Figure 1. Filtering and prioritizing CNVs 
After quality control and manual evaluation of CNVs 374 CNVs larger than 30kb, either 
absent or rare in the modified of the Database of Genomic Variants incorporated in the Nexus 
software remained. 123 out of 374 did not contain genes. 257 were absent and 5 were present 
once in our in-house control database. These 262 CNVs were either gene-rich –containing 
genes- (n=167) or gene-poor. (n=95) Two gene-poor CNVs were suspected of being de novo 
in micro-array trio analysis. Eight out of 74 evaluated CNVs were de novo. Almost all of the 
rare CNVs (140) were widely distributed over the genome. However, our analysis yielded a 
total of 12 loci –containing 29 CNVs- which were affected by a rare CNV more than once and 
were present in more than one patient.  
Figure 2. Size and type distribution of rare CNV  
Total number of rare CNVs in the Erasmus MC-Sophia, Baylor College of Medicine and 
University of Bonn OA/TOF cohort (=375) Homozygous loss is counted as loss. Bins 
represent size ranges e.g. the 50-100kb bin contains all CNVs within the size range of 50 to 
100 kb.  
Figure 3. De novo deletion ranging from chromosomal band 7q35 to 7q36.3.  
Note the loss (red) in the patients logR track and the loss of Heterozygosity (yellow) in the 
patients B-allele frequency (BAF) plot.  qPCR/FISH/MAQ assay validation results in 
supplementary figure 1.  
Figure 4. De novo duplication on chromosome 8p22.  
Note the gain (blue dots/arrow) in the patients’ logR track and allelic imbalance (purple 
dots/arrow) in the patients B-allele frequency (BAF) plot. qPCR/FISH/MAQ assay validation 
results in supplementary figure 1. 
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Table 1 de novo CNVs in this cohort  
None of the parents had oesophageal atresia or trachea-oesophageal fistula. Therefore, main 
focus was on de novo CNVs. Depicted are the eight confirmed (with either qPCR or MAQ 
assay) de novo CNV out of 74 evaluated rare CNVs from the Erasmus MC-Sophia, Baylor 
College of Medicine and University of Bonn cohorts. qPCR/FISH/MAQ assay validation 
results in supplementary figure 1. Chromosome region according to build hg19. 
Table 2. De novo CNVs in OA/TOF patients described in literature 
Depicted are the few published de novo CNVs in patients with nonsyndromic OA/TOF. 
Chromosome region according to build hg19. 
Table 3: Putative deleterious rare CNVs in this cohort 
Total number of putative deleterious CNVs in the Erasmus MC-Sophia, Baylor College of 
Medicine and University of Bonn OA/TOF cohort (=375) Chromosome region according to 
build hg19. All CNVs were absent from our in-house control cohort. U; Inheritance – 
Undetermined, M; Inheritance – Maternal, P; Inheritance – Paternal; NP; No parental DNA 
available, NZ; Nullizygous. 
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Evaluation of impact of rare inherited CNVs; burden test 
The best way to see if a rare CNV is associated to a disease is to do a formal burden test.[1] We are not 
able to do this test for two reasons: (1) the limited number of available patients (375) and controls (3235) 
and (2) the use of different DNA-micro-array technologies (CGH-array, SNP-array) and different chip-
types (e.g. different probes, probe distributions and probe spacing) in patients and control samples.  We 
categorized a CNV in the same bin as it had an overlap of more than 70%, was comparable in size and 
was of the same CNV type (loss or gain). Such a CNV can be heterozygous or homozygous and we can 
use the gene counting method and χ2 test to estimate power and sample size at a significance level of 
P<0.05. Doing so, we concluded that we do not have the power to detect significant differences assuming 
absence in controls and a presence of one (3.4%), two (9.4%), three (12.1%) or four (14.6%) times of an 
overlapping CNV.  Assuming a presence of 4 times (the maximum of overlapping CNVs found in this 
study) and an 1:10 distribution of patients and controls, we would need a tenfold increase in number of 
patients (n=3508) and controls (n= 35075) to detect a difference with an eighty percent power. These 
patient numbers required for rare CNV enrichment analysis are not feasible for a rare disorder as 
esophageal atresia.  
Evaluation of impact of rare inherited CNVs; overlap with previously published studies 
Non-recurrent CNVs seen in our cohort did have overlap with enriched CNVs in these burden studies or 
with CNVs in published in patient databases. For instance, the 15q13.3 deletion seen in male patient 
SKZ_0856 overlaps with a known deleterious CNV[2] seen in patients with a highly variable phenotype 
which include mild to moderate intellectual disability and variable dysmorphic features.[3] The 15q13.3 
paternally inherited loss (chr15:32457092-32771537) seen in patient SKZ_0856 -with OA/TOF, Anal 
atresia, bifid/fused ribs, aortic coarctation, abnormal arterial supply right lung and an abnormal sacrum- 
had overlap with a maternally inherited gain (chr15:32021733-32510863) seen in female patient 280592 –
published in the DECIPHER database- with OA/TOF, laryngeal stenosis, polycystic kidney dysplasia and 
ventricular septal defect. Other CNVs with overlap in our study are the gain involving FAT1 on 4q35.2 in 
patient SKZ_1248, the 6p22 deletion in patient SKZ_1856[2]  and the 2q13 duplication seen in patient 
DE61OSOUKBD100197.[4] Two other rare CNVs containing genes in this study had overlap with 
OA/TOF patients published by the DECIPHER community (http://decipher.sanger.ac.uk). The first one is 
a 11p15.4 gain (chr11:4371631-5253127) seen in patient SKZ_1855 -with isolated OA/TOF- which has  
overlap with the 11p15.4 loss (chr11:4815122-4901807) of unknown inheritance seen in male patient 
288096 with TOF, cardiac anomalies, kidney anomalies, vertebral anomalies and anal atresia. No parental 
DNA was available for patient SKZ_1855, hampering classification of this CNV.  
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DE21OSOUKBD100141; Gain 2q21.1 (Chr2:131349899-131991166) 
 
 
Forward primer Reverse primer Size Chromosome Start Stop 
QPCR_1_2q21.1 CAACCTGTGACAAAGCCAGC TGCAGGGTGTCTTGCTGATG 119 Chr2 131486688 131486806
QPCR_2_2q21.1 AGAGGAAGGACAGCGTGTTC TGACTGTGAGAGCAACTGGG 131 Chr2 131688450 131688580
QPCR_3_2q21.1 GACTGCATCAACATCCGCAC GGGAAGGAAGAGGACCAAGC 115 Chr2 131883442 131883556
 
 
qPCR cutoff for duplication 2.5 and at least two out of three primer pairs matching the criteria. 
0
0.5
1
1.5
2
2.5
3
3.5
Index Father Mother
DE12OSOUKBD100206; Gain 3p26.1(Chr3:8519329-8551649) 
 
 
Amplicon Forward primer Reverse primer Size Chromosome Start Stop 
QPCR_1_3p26.1 TGACAACGACATCTGCAATCG TCCAGGGCCACAGTTAACAC 136 Chr3 8523922 8524057
QPCR_2_3p26.1 AGGTGTCCGGTTAAGTCTCTG TGTAGGCAGAGAGGGGATCC 139 Chr3 8540503 8540641
QPCR_3_3p26.1 GGTGGCTAAGGACCTCAACC AGTTTCCGCGAACAGATGGG 109 Chr3 8543633 8543741
 
 
qPCR cutoff for duplication 2.5 and at least two out of three primer pairs matching the criteria. 
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6
7
8
Index Father Mother
SKZ_2111; loss 7q35q36 (chr7:143,839,360-159,138,663) 
 
 
 
 
BAC clone 7qter (red+ BAC clone RP1-3K23 (green) in father 
 
BAC clone 7qter (red+ BAC clone RP1-3K23 (green) in mother 
 
The 7q35q36 loss is not the result of a balanced translocation in one of the parents  
 
 
 
  
SKZ_1810; Gain 8p22 (chr8:17625479-17813225) 
 
 
 
Amplicon Forward primer Reverse primer Size Chr Start Stop 
FlagMAQ_1810_8p22.1 5'AGCGGATAACAATTTCACACAGGCTCTTCAACTCCAAATCTCAACC-3' 5'-GTTTCTTGATGTGTACGATTAGATTAAGGCAGA-3' 245 chr8 17545893 17546107 
FlagMAQ_1810_8p22.2 5'AGCGGATAACAATTTCACACAGGAGCCATGTGCTGCAAACC-3' 5'-GTTTCTTTGAAGCCTCAAGTGTGAAAGC-3' 169 chr8 17600090 17600228 
FlagMAQ_1810_8p22.3 5'AGCGGATAACAATTTCACACAGGCCAAGTGGAAC CTCCAAGC-3' 5'-GTTTCTTGATGAAGTGTCTCCACGAACC-3' 214 chr8 17669963 17670146 
FlagMAQ_1810_8p22.4 5'AGCGGATAACAATTTCACACAGGGCACAACTGCACCAAAGCTA-3' 5'-GTTTCTTTGGCAGGCACAATACAGG-3' 295 chr8 17754984 17755248 
FlagMAQ_1810_8p22.5 5'AGCGGATAACAATTTCACACAGGAGCTAACATGGCAACAGAATAATG-3' 5'-GTTTCTTGGAAAGAGAATGTCCAAATATGC-3' 180 chr8 17823952 17824101 
 
SKZ_1810; loss 11p14.3 (chr11:21853276-22016176) 
 
 
 
Amplicon Forward primer Reverse primer Size Chr Start Stop 
FlagMAQ_1810_11p14.1 5'AGCGGATAACAATTTCACACAGGAGGCCTACGAGGGAATGC-3' 5'-GTTTCTTGGGCAAACACCAACAGGA-3' 113 chr11 21795830 21795912
FlagMAQ_1810_11p14.2 5'AGCGGATAACAATTTCACACAGGTGAGTATTCAACAGGAACTAAACTGG-3' 5'-GTTTCTTGGTGCAGGCTTTGAGTCC-3' 197 chr11 21849190 21849356
FlagMAQ_1810_11p14.3 5'AGCGGATAACAATTTCACACAGGTGTTGAGCAACCA AGAGAAATTAAG-3' 5'-GTTTCTTCAACAACTAGAATGGTCCACTGA-3' 184 chr11 21918986 21919139
FlagMAQ_1810_11p14.4 5'AGCGGATAACAATTTCACACAGGAGTTGGAGTTATTAAAGGCTGAGGA-3' 5'-GTTTCTTTGTGGCAGGGAGTGAATG-3' 177 chr11 21996140 21996286
FlagMAQ_1810_11p14.5 5'AGCGGATAACAATTTCACACAGGCAGAGCCTCACTACCCACAGA-3' 5'-GTTTCTTTTTAATATTCGCTCTCAATAATGTCC-3' 136 chr11 22067921 22068026
 
SKZ_1662; loss 13q12.11 (chr13:22688792-22981935) 
 
 
 
 
Amplicon Forward primer Reverse primer Size Chr. Start Stop 
FlagMAQ_chr13:22688792-22981935.1 5'AGCGGATAACAATTTCACACAGGGGTGTAGTTTGCTTAATTCACAGG-3' 5'-GTTTCTTAAAGATACCATCGAAACCACTGA-3' 339 chr13 22696898 22697206
FlagMAQ_chr13:22688792-22981935.2 5'AGCGGATAACAATTTCACACAGGAGGACGAGGAAGGGCAGA-3' 5'-GTTTCTTGAAAGGACAGGCTGGAAATG-3' 218 chr13 22761030 22761217
FlagMAQ_chr13:22688792-22981935.3 5' AGCGGATAACAATTTCACACAGGCTTGTTTCGGGAGTCATAAGTCA-3' 5'-GTTTCTTCCCTTTCAATTGTCAACAGCTA-3' 168 chr13 22817621 22817758
FlagMAQ_chr13:22688792-22981935.4 5'AGCGGATAACAATTTCACACAGGTGCTTATCACTGAACCACAACC-3' 5'-GTTTCTTAATCACAAAGGAGCTAGAGGAATG-
3' 
237 chr13 22897279 22897485
FlagMAQ_chr13:22688792-22981935.5 5'AGCGGATAACAATTTCACACAGGGACTTCCAACACCACAAACTAATG-3' 5'-GTTTCTTTCCTAGACACAGCTACCAATGC-3' 287 chr13 22965582 22965838
SKZ_0092; loss 15q11 
 
One polymorphism , in the 15q11 region was detected with WES-CN.  In the upper panel red dots 
indicate loss, two MAQ assay probes (red arrow) inside the deleted region, confirm this loss. SNP-array 
resolution was not enough to call this loss. This is not one of the 167 rare CNVs. 
  
SKZ_2111; Gain 16p13.3(chr16:14,985,615-17,000,304) 
 
 
Gain in HG19:  
Amplicon Forward primer Reverse primer Size Chr Start Stop 
FlagMAQ_2111_2.1 5'AGCGGATAACAATTTCACACAGGCAGGGAGACACCATGCAGA-3' 5'-GTTTCTTGGTATGATGAGAGAGGTGAAGGA-3' 173 chr16 15141570 15141712
FlagMAQ_2111_2.2 5'AGCGGATAACAATTTCACACAGGGTCGACCCTTCCCAAACC-3' 5'-GTTTCTTTGCAATGGAAGATGAAGAGGA-3' 126 chr16 15586155 15586250
FlagMAQ_2111_2.3 5'AGCGGATAACAATTTCACACAGGCTGGGTGAAGAGGCCAAGT-3' 5'-GTTTCTTTGGCCACCCTACAGACAGA-3' 134 chr16 16061100 16061203
FlagMAQ_2111_2.4 5'AGCGGATAACAATTTCACACAGGTGGATGTGAGAAATGCCAAGT-3' 5'-GTTTCTTGGAGGATGAGGAGCAAACC-3' 216 chr16 16965277 16965462
SKZ_21q22.2; Gain 21q22.2 (chr21:40,095,493-40,160,135) 
 
 
Amplicon Forward primer Reverse primer Size Chr. Start Stop 
FlagMAQ_chr21:40100880-40154748.1 5'AGCGGATAACAATTTCACACAGGAACTTCGCCTCTTGGAACC-3' 5'-GTTTCTTAATTCCTCATCACATGGGTCA-3' 131 chr21 40102211 40102311
FlagMAQ_chr21:40100880-40154748.2 5'AGCGGATAACAATTTCACACAGGCTCCCAAATGCACTGAAATG-3' 5'-GTTTCTTAGGTGATAGAATGGGTGCTCTTA-3' 271 chr21 40117025 40117265
FlagMAQ_chr21:40100880-40154748.3 5'AG CGGATAACAATTTCACACAGGCAGGCAGACAGCTCACGTT-3' 5'-GTTTCTTAGAGAGGCACAGGCACAGA-3' 100 chr21 40125236 40125305
FlagMAQ_chr21:40100880-40154748.4 5'AGCGGATAACAATTTCACACAGGCTGCAAATACAGTGCAAACTGA-3' 5'-GTTTCTTTTCCTCCATCACTTTCTTTAACTTC-3' 122 chr21 40144161 40144252
FlagMAQ_chr21:40100880-40154748.5 5'AGCGGATAACAATTTCACACAGGCAGAGAGAGCAACAAACAATGC-3' 5'-GTTTCTTGCTGTGGTGATGAGGGCTA-3' 110 chr21 40154178 40154257
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Study design 
We assessed the CNVs according to the consensus statement for chromosomal micro-array 
analysis described by Miller and co-workers.17 Our study design was based on the assumptions that 
CNVs are most likely to be causal for the abnormal phenotype in congenital anomalies if (I) a CNV is 
absent in large cohorts of unaffected individuals, (II) is absent in the unaffected parents of the affected 
individual and (III) and if it targets relevant genes or non-coding RNAs. Recurrence of loci affected by 
de novo CNVs in single cases could indicate loci harbouring genes mutated or otherwise affected in 
larger disease cohorts.  
As OA/TOF disease frequency ranges between 2-3 in 10,000 live births (0.0002 to 0.0003), 
we classified CNVs to be rare if they were absent or present once in our in-house cohort of unaffected 
individuals. This cohort contains high-quality data of CNVs in autosomes (n=3,235 individuals) and 
sex chromosomes (n= 1,859 individuals). Overlap with one CNV in our in-house cohort reflects a 
population frequency of 0.0003 for autosomes and of 0.00054 for sex chromosomes. Inherited CNVs 
affect exactly the same locus as in their unaffected parent. As a single entity, these CNVs are therefore 
assumed not to be sufficient to give a severe phenotype. However, these CNVs might be of interest if 
present in more patients that share phenotypical characteristics, as they can act as a modifier in a 
multiple hit model, or as the second hit in a recessive condition. Special interest is given to shared 
anatomical malformations in addition to OA/TOF as these could hint at a specific sub-population in 
the cohort. Therefore, we also evaluated rare CNVs if they had overlapping loci in multiple patients 
with shared phenotypical characteristics.  
Patient cohort 
This study was approved by the institutional ethics committee of each participating centre, and 
was conducted in accordance with the principles of the Declaration of Helsinki. Patients with OA/TOF 
(isolated or non-isolated) were identified from the medical records. All patient records were reviewed 
by the treating physicians or geneticists of each participating centre. After retrieval of parental 
informed consent, blood was drawn from a total of 375 patients and their parents, comprising 239 
patients from the Erasmus MC- Sophia, 28 from the Baylor College of Medicine, and 108 from a 
German multi-centre study regarding the genetic and environmental cause of OA/TOF (“The genetic 
risk for oesophageal atresia consortium [GREAT-consortium]”). Contact with patients and their 
families was established through their treating physicians or the German patient-support organization 
for patients with disorders of the oesophagus (KEKS e.V.; http://www.keks.org/). Previously, 68 
patients of the Erasmus MC-Sophia and Baylor College of Medicine cohorts were evaluated in a study 
describing CNVs in VACTERL association.16  
GTG-banded karyotyping and multiplex ligation-dependent probe amplification (MRC 
Holland, Amsterdam, the Netherlands) have ruled out the presence of large structural rearrangements 
 
   
or aneuploidies in the majority of enrolled patients from the Erasmus MC- Sophia and the Baylor 
College of Medicine.18 The German cohort was exclusively screened with micro-array. From 2009 
onwards micro-array was the first tier-diagnostic tool used in the clinic, replacing GTG-banded 
karyotyping as a screening tool for large CNVs and aneuploidies. Patients born before 2009 were 
almost exclusively screened in a research setting and were enriched for the more complex non-isolated 
OA/TOF phenotypes. This causes over-representation for non-isolated OA/TOF patients in our cohort. 
Hence, over-representation of complex cases in this study is the result of selection bias and is not 
indicative for an actual deviance from the general isolated OA prevalence. 
Literature search 
We reviewed the literature (PubMed) in order to identify previously described disease-causing 
CNVs described in individuals with OA and / or TOF. Search terms included CNV, CNA (Copy 
Number Alteration), micro-array analysis, oesophageal atresia, tracheoesophageal fistula and 
VACTERL association. 
DNA isolation  
For the Dutch and American cohorts DNA for genomic analysis was extracted from peripheral 
blood, saliva and fibroblast cells with the Puregene DNA purification kit (Gentra Systems, USA) or 
the QIAamp DNA Blood Midi Kit (Qiagen, Inc., Hilden, Germany) or the Oragene DNA Kit. (DNA 
Genotek Inc., Ontario, Canada)  DNA quality was evaluated with the Thermo Scientific NanoDrop 
2000 (Thermo Fisher Scientific Inc., Waltham, USA), and dsDNA quantity with the Quant-iT™ 
PicoGreen ® dsDNA kit. (Invitrogen, Carlsbad, CA, USA). In the German Cohort DNA for genomic 
analysis was either extracted from peripheral blood or saliva, using the Chemagic Magnetic Separation 
Module I (ParkinElmer chemagen, Baesweiler, Germany) or the Oragene DNA Kit  respectively.  
Array-based molecular karyotyping    
In the Dutch and American cohorts karyotyping was performed according to standard 
analytical methods. All DNA samples were  tested for subtelomeric aberrations with Multiplex 
ligation-dependent probe amplification analysis, using the P036E1 and P070A2 Salsa telomere kits 
(MRC Holland, Amsterdam, and the Netherlands) as published previously. [1] High-resolution 
analyses for genomic imbalances present in the DNA of these patients were performed using single-
nucleotide polymorphism (SNP) microarrays (Illumina Inc., San Diego, CA, USA and Affymetrix Inc. 
Santa Clara, CA, USA) and CGH  oligonucleotide-based arrays (Agilent Inc., San Diego, CA, USA) 
using standard protocols. Micro-array analysis in the American and Dutch cohort was initially 
performed using three types of array chips (GeneChip Human Mapping 250K Nsp, 12-
HumanCytoSNP DNA Analysis BeadChips v1-v2.1, and Agilent Human Genome CGH 105K and 
244K), later these were replaced by chips with a higher resolution (Illumina Human 610-Quad 
Beadchip and Illumina HumanOmniExpress BeadChip, Illumina Infinium CytoSNP-850k BeadChip 
and Agilent SurePrint G3 Human CGH 1M Oligo Microarray Kits G4411B/G4447). The majority of 
the Dutch cohort cases were processed on more than one array chip type. Material from all German 
patients enrolled in this study was screened using the HumanOmniExpress 12 v1.1 chip (Illumina Inc., 
San Diego, CA, USA). 
Normalized output was generated using Feature Extraction software  (v.9.1), alongside CGH 
Analytics software (v.3.3.28), with Affymetrix GTYPE (v.4.1, Affymetrix, Santa Clara, CA) or 
Illumina Genomestudio (v.2011.1, Illumina, San Diego, CA, USA), depending on chip type. CNVs in 
patient samples were visualized as log2-Ratios (Log2R) detected through comparison of patient probe 
intensity data with those of a virtual reference set of 270 HapMap samples of various ancestries 
(Illumina manifest file) or by comparison with sex matched controls of unaffected, unrelated 
individuals or reference DNA (Promega Corporation, Madison, WI). Since the German cohort was 
coherently processed on one chip type only, normalized output could be generated using the 
Genomestudio (v. 2011.1) genotyping module (v.1.9.4, Illumina, San Diego, CA, USA).    
CNV filtering  
For SNP-arrays, potential Copy Number Variants (CNVs) were estimated using a combination 
of allelic ratio (B-Allele Frequency, BAF) and SNP array copy number state (Log2R), utilizing 
Hidden-Markov-Model based algorithms. For this purpose Biodiscovery Nexus CN7.5  (Biodiscovery 
Inc, Hawthorne, CA, USA) was used for both cohorts. In the Nexus software,  segmentation 
significance threshold was set at 5.0E-7 with a minimum of 5 probes per segment and a maximum 
probe spacing of 1,000 kb.  The log2R-ratio thresholds were set at +0.18 (single copy gain), -0.18 
(single copy loss), 0.4 (gain of two or more copies) and -1.1 (homozygous loss). The Homozygous 
Frequency/ Homozygous Value/ Heterozygous Imbalance Threshold were set at 0.95/0.8/0.4. The 
minimum LOH length was set at 100 kb and minimum SNP probe density, at 10 probes/Mb.  Gender 
correction was used with a 3:1 sex chromosome gain threshold of 1.2 and a 4:1 sex chromosome gain 
threshold of 1.7. Log2R ratios of CGH-array results were determined with the ADM2 algorithm with 
filtering options of a minimum of 3 probes. (log2Ratio) >0.3. Each segment deviating from the normal 
situation was reviewed by visual inspection in Nexus CN 7.5. During the course of this study, the 
genome build switched from build hg18 to hg19. Not all arrays-chips could be re-processed or re-
analyzed in the new genome build. For these array chips, the detected CNV regions were transformed 
using the UCSC lift-over tool and re-evaluated in the hg19 build for overlap with known 
polymorphisms (see below) and overlap with our in-house cohort (see below).  Re-analysis of SNP-
array in the new genome build, together with improved segmentation and waving correction 
algorithms resulted in the loss of several low confidence CNV calls.  
Each observed CNV  was  compared to the frequency of that CNV at the particular locus in a 
modified version (i.e. excluding BAC arrays and small InDels) of the Database of Genomic Variants 
 
   
(DGV, http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36/hg19) incorporated in the Biodiscovery 
Nexus CN7.5 analysis package. Only those CNVs with a physical overlap with a DGV locus less than 
70% and which occurred  ≤5 times in the DGV were compared to an in-house control database of 
unrelated and unaffected parental samples and healthy control individuals. This cohort contains high-
quality data of CNVs in autosomes (n=3235 individuals) and sex chromosomes (n= 1859 individuals). 
Overlap with one CNV in our in-house cohort reflects a population frequency of 0.0003 for autosomes 
and of 0.00054 for sex-chromosomes. We only considered CNVs which were either absent or present 
once for further  analysis.  All CNVs passing the filter criteria were evaluated manually by comparing 
the CNV to its presence in the most current versions of the database of genomic variation (DGV, 
http://dgv.tcag.ca/dgv/app/home), ISCA (http://dbsearch.clinicalgenome.org/search/), ClinGen 
(https://www.clinicalgenome.org/data-sharing/clinvar/)  and DECIPHER. 
(http://decipher.sanger.ac.uk)   
We searched for overlap in large CNV cohorts of control individuals published by Cooper et 
al.[2], Coe et al.[3] and Kaminsky et al.[4] We also evaluated the CNVs significantly different in these 
studies between patients and controls. As we used different array chips in this experiment, each with 
different marker spacing, distribution and content, we set a size CNV restriction threshold of minimum 
30kb for single events, except when evaluating parental and patient SNP-arrays (trio analysis) . In trio 
analysis, all CNVs containing more than five probes were visually inspected using Nexus CN 7.5. We 
confirmed Copy Number (CN) state and inheritance pattern of private and rare CNVs if their size 
exceeded the restrictions thresholds and if the CNV contained genes or micro RNA’s. All patient 
CNVs were visually re-evaluated using the Nexus software package e.g. we evaluated if CN state 
matched the allelic state of a CNV type. 
Validation of microarray results 
In the Dutch and American cohort, putative de novo events were confirmed via patient and 
parental copy number quantification using either additional SNP array, Fluorescence In Situ 
Hybridization (FISH) and/or Multiplex Amplicon Quantification (MAQ)(MultiplicoM N.V., Niel, 
Belgium) as well as real time quantitative PCR, the procedure also used for confirmation in the 
German cohort.  At least two primer pairs for qPCR were designed within the putative CNVs using 
Primer Express Software v2.0 (Applied Biosystems, Foster City, CA, USA) for the Dutch cohort and 
Primer3web (v4.0.0.; http://primer3.ut.ee/)[5-7] for the German cohort. For the Dutch cohort the 
absence of SNPs in primer sequences was confirmed in dbSNP (build 135) and specificity of 
amplified region determined with the University of Santa Cruz (UCSC) in silico PCR and melting-
curve analysis. Primer pairs with repeats in their resulting amplicon, according to CENSOR repeat 
masker[8] were excluded. Sequences for the German cohort were checked for SNPs and specificity 
using  the UCSC human genome browser build 19 (http://genome.ucsc.edu).[9] QPCR experiments for 
the Dutch cohort were performed using a LightCycler 1.5 instrument and LightCycler FastStart DNA 
Master SYBER Green I kit with C14ORF145 as a control locus. (Roche Molecular Diagnostics, 
Indianapolis, IN, USA) Locus exon 4 of the KIAA1279-gene was used as a control.[10] Cut-off values 
of <0.7 were used for deletions and values of >1.3  for duplications. For the German cohort QPCR 
experiments were performed on a LightCycler 480 II (Roche Molecular Diagnostics Indianapolis, IN, 
USA) in combination with Power SYBR Green Master Mix (Applied Biosystems, Foster City, USA). 
In order to normalize threshold cycle (Ct) values, each samples Ct value was compared to those of 
three reference genes (BCN1, CFTR, RNAseP subunit p38). Analysis was done as described by Scott 
et al.[11] In both cohorts each sample, including the no-template control (NTC) and control DNA, was 
run in triplicate.  
For FISH confirmation, BAC-clones were selected from the UCSC genome browser and 
ordered from BACPAC Resources. After isolation of the BAC-DNA, the probes were amplified, 
labeled and used for FISH, according to standard protocols as described earlier.[12] The MAQ assay is 
a PCR-based-amplification method which uses 6 primer pairs on different loci for sample-internal 
copy number normalization, maximal 5 CNV specific primer pairs developed with the manufacturers’ 
software package, and one type of FAM labeled primer specific to the sequence-tagged forward 
primers to amplify 20ng of dsDNA input. The DNA of 4 unaffected, unrelated individuals was used as 
sample-external copy number normalization. We amplified the DNA according to the manufacturer’s 
protocol in a thermocycler with a heated lid, and analyzed the resulting FAM-labelled amplicons of 
patient, parental and controls using an automated sequencer (ABI 3730XL, Applied Biosystems, 
Foster City, CA, USA). This capillary electrophoresis step separates fragments on the basis of their 
length, these differences in amplicon length make multiplexing possible. The differences in 
fluorescence intensity reflect copy number state and were visualized in the MAQ-S analysis tool 
(Multiplicom Inc., Niel, Belgium) which compares amplicon size to the Genescan LIZ 500 size 
standard and normalizes copy number state to the internal amplicons and 4 external controls. 
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Supplementary Table 1 Genomic coordinates and patient phenotypes of rare overlapping inherited CNVs 
Internal Type Chr Cytoband Chromosome region HG19 Length Genes affected Inheritance Classification 
SKZ_1112 Gain 3 p14.1 chr3:64992802-65051455 58653 ADAMTS9-AS2, BC040632 no parental DNA  Uncertain 
SKZ_0999 Gain 3 p14.1 chr3:64993928-65024494 30566 ADAMTS9-AS2 maternal Uncertain : likely benign 
DE82OSOUKBD100013 Loss 8 p23.2 chr8:3619348-3650542 31195 CSMD1 undetermined Benign 
DE27OSOUKBD100324 Loss 8 p23.2 chr8:4323965-4359306 35342 CSMD1 undetermined Benign 
DE37OSOUKBD100144 Loss 9 p24.1 chr9:8802640-8836439 33800 PTPRD undetermined Uncertain- likely benign 
DE60OSOUKBD100312 Loss 9 p23 chr9:9919638-9990269 70632 PTPRD undetermined Uncertain- likely benign 
DE63OSOUKBD100161 Gain 9 q34.3 chr9:138147997-138238503 90507 C9orf62 undetermined Benign 
DE63OSOUKBD100161 Gain 9 q34.3 chr9:138147997-138238503 90507 C9orf62 undetermined Benign 
DE14OSOUKBD100461 Loss 10 p12.33 chr10:18550958-18592873 41916 CACNB2 undetermined Uncertain 
DE37OSOUKBD100047 Loss 10 p12.33 chr10:18550958-18583866 32909 CACNB2 undetermined Uncertain 
SKZ_0773 Loss 11 q22.1 chr11:99497530-99583304 85774 CNTN5 undetermined Benign 
DE43OSOUKBD100133 Loss 11 q22.1 chr11:99519242-99568648 49407 CNTN5 undetermined Benign 
DE76OSOUKBD100315 Loss 11 q22.1 chr11:99519242-99568648 49407 CNTN5 undetermined Benign 
SKZ_1432 Loss 11 q22.1 chr11:99519242-99568648 49406 CNTN5 no parental DNA  Benign 
DE35OSOUKBD100471 Gain 12 q24.12 - q24.13 chr12:112183225-112327166 143942 ACAD10- MAPKAPK5 undetermined Benign 
SKZ_1516 Gain 12 q24.12 chr12:112183225-112327166 143941 ACAD10- MAPKAPK5 maternal Benign 
148-04-01 Gain 12 q24.12 chr12:112183921-112318246 134325 ACAD10- MAPKAPK5 maternal Benign 
SKZ_1976 Gain 13 q31.3 chr13:92958981-93035128 76147 GPC5 maternal Benign 
SKZ_1746 Gain 13 q31.3 chr13:92979291-93049171 69880 GPC5 maternal Benign 
DE44OSOUKBD100309 Gain 15 q26.3 chr15:102325461-102373183 47723 OR4F6, OR4F15 undetermined Benign 
DE76OSOUKBD100315 Gain 15 q26.3 chr15:102332446-102368280 35835 OR4F6, OR4F15 undetermined Benign 
SKZ_2111 Gain 16 p13.11 chr16:14985615-17000304 2014689 NOMO1-NPIP de novo Uncertain : likely pathogenic 
SKZ_1988 Gain 16 p13.11 chr16:15034035-15998820 964785 NPIP-FOPNL paternal Uncertain 
SKZ_1150 Gain 16 p13.11 chr16:15539023-16291541 752518 C16ORF45-ABCC6 paternal Uncertain 
DE45OSOUKBD100291 Loss 16 q24.1 chr16:84429584-84490643 61060 ATP2C2 undetermined Benign 
SKZ_1500 Loss 16 q24.1 chr16:84435058-84470476 35418 ATP2C2, KIAA0703 maternal Benign 
DE94OSOUKBD100282 Gain X p22.33 chrX:370599-612414 241816 SHOX undetermined Uncertain- likely benign 
SKZ_1508 Gain X p22.33 chrX:405941-596245 218468 SHOX maternal Uncertain- likely benign 
SKZ_0374 Gain X p22.33 chrX:407015-1008051 788690 SHOX maternal Uncertain- likely benign 
   
 
  
Casenr Gender Major anomalies 
SKZ_1112 M EA 
SKZ_0999 M EA/TEF 
DE82OSOUKBD100013 F EA, developmental delay 
DE27OSOUKBD100324 F EA, Atrial septum defect I, tracheomalacia 
DE37OSOUKBD100144 M EA 
DE60OSOUKBD100312 F EA, alopecia, Cafe-au-lait spots, eye anomalies 
DE63OSOUKBD100161 F EA, vesicourethral reflux, PUV 
DE14OSOUKBD100461 F EA 
DE37OSOUKBD100047 M EA, tracheomalacia 
SKZ_0773 F EA/TEF, vertebral anomalies, anal , genital and ear anomalies, renal anomalies, upper limb anomalies, cleft lip+jaw+palate, duodenal atresia 
DE43OSOUKBD100133 F EA, brochial anomalies 
DE76OSOUKBD100315 F EA, lung anomalies 
SKZ_1432 M EA/TEF, anal anomalies, renal anomalies, urethral fistula and atresia, genital anomalies 
DE35OSOUKBD100471 M Esophageal stenosis, achalasia 
SKZ_1516 F EA/TEF, ventricular septal defect, right sided aortic arch 
148-04-01 F TEF, ventricular septal defect, anal atresia and vertebral anomalies 
SKZ_1976 M EA/TEF, tracheo-laryngomalacia 
SKZ_1746 M EA/TEF 
DE44OSOUKBD100309 F EA, tracheomalacia 
DE76OSOUKBD100315 F EA, lung anomalies 
SKZ_2111 M TEF, anal anomaly, multiple VSDs, hypospadia 
SKZ_1988 F EA/TEF, anal anomalies, 
SKZ_1150 F EA/TEF + Atrio-ventricular septal defect 
DE45OSOUKBD100291 F EA, hypoplastic thumb, Atrial septum defect II, kidney anomalies, tracheomalacia 
SKZ_1500 F EA/TEF, anorectal anomaly,  
DE94OSOUKBD100282 M EA, tracheomalacia, scoliosis, undescended testicle 
SKZ_1508 M EA/TEF, upper limb anomalies Atrial septum defect, dysmorphisms 
 
 
Internal Type Chr Cytoband Chromosome region HG19 Length Inheritance CNV-frequency cohort multiple ISCA DGV database web ClinGen CNV (likely) benign Control group developmental delay Authors classification
148-13-01 Loss 1 q24.2 chr1:168441289-168697617 256328 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1545 Loss 1 q25.2 chr1:178806664-181082264 2275600 Inheritance - Paternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
DE84OSOUKBD100074 Gain 1 q43 chr1:241155581-241186738 31158 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE83OSOUKBD100480 Gain 1 q44 chr1:246256444-246700236 443793 Inheritance - Undetermined 0.000 - Benign Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1840 Loss 1 q32.3 chr1:213092201-213176992 84791 No parental DNA available 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain
DE21OSOUKBD100141 Gain 2 q21.1 chr2:131485402-132024166 538765 Inheritance - de novo 0.000 - Uncertain Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
SKZ_0708 Loss 2 q22.1 chr2:137827978-138371164 543186 Inheritance - Maternal 0.000 - Uncertain- likely benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE82OSOUKBD100013 Gain 2 q14.2 chr2:121588391-121754337 165947 Inheritance - Undetermined 0.000 - Uncertain- likely pathogenic Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_2051 Loss 2 q23.1 chr2:149089645-149192958 103313 Inheritance - Paternal 0.000 - no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE69OSOUKBD100150 Loss 2 q21.2 chr2:133927604-133963658 36055 Inheritance - Undetermined 0.000 - no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Benign
SKZ_0739 Loss 2 p22.1 chr2:39982433-40037717 55284 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1307 Gain 2 p16.1 chr2:56277274-56381718 104444 Inheritance - Paternal 0.000 - Uncertain Benign Benign Uncertain- likely benign Benign
DE54OSOUKBD100323 Gain 2 q37.1 chr2:233181492-233325849 144358 Inheritance - Undetermined 0.000 - Benign Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_0832 Gain 2 p16.1 chr2:61271844-61368778 96934 Inheritance - Paternal 0.000 - no comparable CNVs no comparable CNVs Benign Uncertain- likely benign Benign
SKZ_1381 Gain 2 p12 chr2:77199019-77249536 50517 Inheritance - Maternal 0.000 - no comparable CNVs Uncertain- likely benign Benign no comparable CNVs Uncertain- likely benign
SKZ_1780 Loss 2 p12 chr2:78306103-78697833 391730 Inheritance - Maternal 0.000 - Uncertain- likely benign Benign Uncertain- likely benign Uncertain- likely benign Benign
SKZ_0887 Loss 2 q37.1 chr2:231012029-231089979 77950 Inheritance - Paternal 0.000 - Uncertain no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_2051 Gain 2 q35 chr2:218647714-219053933 406219 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain
DE61OSOUKBD100197 Gain 2 q13 chr2:111186302-113273657 2087356 Inheritance - Undetermined 0.000 - Uncertain- likely benign Uncertain Benign Uncertain- likely pathogenic Uncertain- likely pathogenic
SKZ_0999 Gain 3 p14.1 chr3:64993928-65024494 30566 Inheritance - Maternal 0.000 1 no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
DE62OSOUKBD100179 Loss 3 q22.2 chr3:134978716-135053549 74834 Inheritance - Undetermined 0.000 - no comparable CNVs Benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign
DE26OSOUKBD100342 Loss 3 p14.2 chr3:62955270-62998884 43615 Inheritance - Undetermined 0.000 - no comparable CNVs Benign no comparable CNVs Benign Benign
SKZ_1112 Gain 3 p14.1 chr3:64992802-65051455 58653 No parental DNA available 0.000 1 no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain
DE07OSOUKBD100005 Loss 3 p12.3 chr3:76848167-76951689 103523 Inheritance - Undetermined 0.000 - Uncertain Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_0374 Gain 3 q13.13 chr3:108616806-109014594 397788 Inheritance - Paternal 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE92OSOUKBD100221 Loss 3 p12.1 chr3:85561190-85612793 51604 Inheritance - Undetermined 0.000 - Benign Benign Benign Uncertain- likely benign Benign
SKZ_1416 Gain 3 p12.3 - p12.2 chr3:80453558-83463345 3009787 Inheritance - Maternal 0.000 - Uncertain no comparable CNVs Uncertain- likely benign Uncertain- likely benign Benign
DE12OSOUKBD100206 Gain 3 p26.1 chr3:8520585-8552850 32266 Inheritance - de novo 0.000 - Uncertain Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain
SKZ_2032 Gain 3 p12.1 chr3:86387381-86615770 228389 Inheritance - Maternal 0.000 - Uncertain no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_0367 Gain 3 q22.1 chr3:133034333-133089757 55424 No parental DNA available 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain
DE62OSOUKBD100179 Gain 4 q32.1 chr4:156745682-157287454 541773 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
SKZ_1523 Gain 4 p15.32 chr4:16922258-17800667 878409 No parental DNA available 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE53OSOUKBD100147 Loss 4 q13.2 chr4:69668636-69713319 44684 Inheritance - Undetermined 0.000 - no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1002 Loss 4 p16.1 chr4:7696394-7760459 64065 Inheritance - Paternal 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1248 Gain 4 q35.2 chr4:187540292-187849681 309389 Inheritance - Maternal 0.000 - Uncertain Uncertain Uncertain- likely benign Uncertain Uncertain- likely pathogenic
DE05OSOUKBD100138 Loss 4 q28.1 chr4:125251081-128286629 3035549 Inheritance - Undetermined 0.000 - Pathogenic Pathogenic no comparable CNVs no comparable CNVs Uncertain- likely benign
DE69OSOUKBD100150 Gain 5 q35.1 chr5:171395554-171508587 113034 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
DE11OSOUKBD100224 Gain 5 q23.1 chr5:120513455-120921346 407892 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_0255 Loss 5 q31.1 chr5:131145181-131266601 121420 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1925 Gain 5 p14.1 chr5:25017057-25426009 408952 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1248 Gain 5 p15.1 chr5:16652934-16771046 118112 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1453 Gain 5 q12.1 chr5:59718323-59752640 34317 Inheritance - Maternal 0.000 - no comparable CNVs Benign Uncertain- likely benign Benign Benign
SKZ_1800 Gain 5 p15.31 - p15.2 chr5:7198626-8305678 1107052 Inheritance - Maternal 0.000 - Uncertain Uncertain no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1032 Loss 5 q11.2 chr5:53784524-54985838 1201314 Inheritance - Paternal 0.000 - Uncertain no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
DE85OSOUKBD100056 Gain 6 q16.3 chr6:101950970-102062025 111056 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign
DE53OSOUKBD100050 Gain 6 q26 chr6:162201050-162260159 59110 Inheritance - Undetermined 0.000 - no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Benign
DE61OSOUKBD100294 Loss 6 p21.33 chr6:31969589-32007227 37639 Inheritance - Undetermined 0.000 - Uncertain- likely benign Benign Benign Benign Benign
DE11OSOUKBD100127 Gain 6 p21.31 Chr6:35285720-35434273 148554 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1506 Loss 6 q23.2 chr6:134730991-135020544 289553 Inheritance - Paternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1856 Loss 6 p22.3 chr6:20884837-21082258 197421 No parental DNA available 0.000 - no comparable CNVs Uncertain- likely pathogenic no comparable CNVs no comparable CNVs Uncertain- likely pathogenic
148-16-01 Loss 7 q34 chr7:142825643-142890809 65166 Inheritance - Maternal 0.000 - no comparable CNVs Benign no comparable CNVs Benign Uncertain- likely benign
SKZ_1174 Gain 7 q35 chr7:143342375-143913713 571338 Inheritance - Maternal 0.000 - Benign Benign Benign Uncertain- likely benign Benign
SKZ_1662 Gain 7 q36.3 chr7:157730598-157826278 95680 Inheritance - Paternal 0.000 - Uncertain- likely benign Benign Uncertain- likely benign Uncertain- likely benign Benign
148-17-01 Loss 7 p22 chr7:6123758-6139997 16239 Inheritance - not Maternal 0.000 - Benign Benign Benign no comparable CNVs Uncertain- likely benign
DE20OSOUKBD100450 Loss 7 q21.13 chr7:88645832-89092714 446883 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1035 Gain 7 p21.1 chr7:17243791-17590700 346909 Inheritance - Paternal 0.000 - Uncertain Benign Benign Benign Benign
SKZ_1035 Gain 7 p14.1 chr7:40156332-40204960 48628 Inheritance - Paternal 0.000 - no comparable CNVs Benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_2111 Loss 7 q35q36.3 chr7:143839360-159138663 15299303 Inheritance - de novo 0.000 - Pathogenic no comparable CNVs no comparable CNVs no comparable CNVs Pathogenic
DE82OSOUKBD100013 Loss 8 p23.2 chr8:3619348-3650542 31195 Inheritance - Undetermined 0.000 2 no comparable CNVs Uncertain- likely benign Benign no comparable CNVs Benign
DE27OSOUKBD100324 Loss 8 p23.2 chr8:4323965-4359306 35342 Inheritance - Undetermined 0.000 2 Uncertain- likely benign Uncertain- likely benign Benign no comparable CNVs Benign
DE18OSOUKBD100098 Loss 8 p23.1 chr8:10447116-10504819 57704 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
DE92OSOUKBD100221 Loss 8 q13.3 chr8:71608781-71646728 37948 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_0426 Gain 8 q24.3 chr8:142438569-142482615 44046 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign Benign
SKZ_1923 Gain 8 p23.3 chr8:1445011-1797072 352061 Inheritance - Paternal 0.000 - no comparable CNVs Benign Benign Uncertain- likely benign Benign
SKZ_1810 Gain 8 p22 chr8:17592647-17859657 267010 Inheritance - de novo 0.000 - Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
DE63OSOUKBD100161 Gain 9 q34.3 chr9:138147997-138238503 90507 Inheritance - Undetermined 0.000 4 Uncertain- likely benign Benign Benign Uncertain- likely benign Benign
DE63OSOUKBD100161 Gain 9 q34.3 chr9:138147997-138238503 90507 Inheritance - Undetermined 0.000 4 Uncertain- likely benign Benign Benign Uncertain- likely benign Benign
DE12OSOUKBD100303 Gain 9 q34.2 chr9:136850292-137153876 303585 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign
DE37OSOUKBD100144 Loss 9 p24.1 chr9:8802640-8836439 33800 Inheritance - Undetermined 0.000 3 no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE60OSOUKBD100312 Loss 9 p23 chr9:9919638-9990269 70632 Inheritance - Undetermined 0.000 3 no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1825 Loss 9 p22.3 chr9:15300542-15381614 81072 Inheritance - Maternal 0.000 - Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign Benign
DE37OSOUKBD100047 Loss 10 p12.33 chr10:18550958-18583866 32909 Inheritance - Undetermined 0.000 5 no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
DE14OSOUKBD100461 Loss 10 p12.33 chr10:18550958-18592873 41916 Inheritance - Undetermined 0.000 5 no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
Internal Type Chr Cytoband Chromosome region HG19 Length Inheritance CNV-frequency cohort multiple ISCA DGV database web ClinGen CNV (likely) benign Control group developmental delay Authors classification
DE60OSOUKBD100118 Gain 11 q22.1 chr11:101397368-101472351 74984 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_2039 Gain 11 q22.3 chr11:103971318-104028957 57639 No parental DNA available 0.000 - Uncertain Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_2026 Loss 11 p15.4 chr11:1115899-1261163 145264 No parental DNA available 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE63OSOUKBD100355 Gain 11 p15.2 chr11:14865608-14906548 40941 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1441 Loss 11 p12 chr11:40567422-40660470 93048 Inheritance - Undetermined 0.000 - Benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1810 Loss 11 p14.3 chr11:21836986-22032466 195480 Inheritance - de novo 0.000 - Uncertain Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_0773 Loss 11 q22.1 chr11:99497530-99583304 85774 Inheritance - Undetermined 0.001 6 no comparable CNVs Benign Benign Uncertain- likely benign Benign
DE43OSOUKBD100133 Loss 11 q22.1 chr11:99519242-99568648 49407 Inheritance - Undetermined 0.001 6 no comparable CNVs Benign Benign Uncertain- likely benign Benign
DE76OSOUKBD100315 Loss 11 q22.1 chr11:99519242-99568648 49407 Inheritance - Undetermined 0.001 6 no comparable CNVs Benign Benign Uncertain- likely benign Benign
SKZ_1432 Loss 11 q22.1 chr11:99519242-99568648 49406 No parental DNA available 0.001 6 no comparable CNVs Benign Benign Uncertain- likely benign Benign
SKZ_0400 Gain 11 q13.5 chr11:76268060-76417696 149636 Inheritance - Paternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1415 Loss 11 q14.2 - q14.3 chr11:87099219-91921385 4822166 Inheritance - Maternal 0.000 - Uncertain no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1855 Gain 11 p15.4 chr11:4371631-5253127 881496 No parental DNA available 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely pathogenic
DE04OSOUKBD100156 Gain 12 q24.11 chr12:109549884-109667024 117141 Inheritance - Undetermined 0.000 - Benign Uncertain- likely benign Benign Uncertain- likely benign Benign
DE35OSOUKBD100471 Gain 12 q24.12 - q24.13 chr12:112183225-112327166 143942 Inheritance - Undetermined 0.000 7 Benign Uncertain- likely benign Benign Uncertain- likely benign Benign
SKZ_0999 Gain 12 p13.2 chr12:10423943-10552714 128771 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1845 Gain 12 q24.31 chr12:123596909-123989546 392637 No parental DNA available 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_0406 Gain 12 q24.32 chr12:127488730-127837052 348322 Inheritance - Undetermined 0.000 - Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
SKZ_0703 Gain 12 q24.33 chr12:133199968-133337730 137762 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1506 Gain 12 p13.33 chr12:706022-1125143 419121 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1516 Gain 12 q24.12 chr12:112183225-112327166 143941 Inheritance - Maternal 0.000 7 Benign Benign Benign Uncertain- likely benign Benign
148-04-01 Gain 12 q24.12 chr12:112183921-112318246 134325 Inheritance - Maternal 0.000 7 Benign Benign Benign Uncertain- likely benign Benign
DE76OSOUKBD100315 Gain 12 q22 chr12:95530434-95627379 96946 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1301 Gain 12 p13.31 chr12:8069848-8101856 32008 Inheritance - Maternal 0.000 - Benign Benign Benign Uncertain- likely benign Benign
SKZ_1790 Loss 12 q21.31 chr12:83765377-84013252 247875 Inheritance - Maternal 0.000 - no comparable CNVs Uncertain no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE93OSOUKBD100203 Loss 13 q12.12 chr13:23803922-23853233 49312 Inheritance - Undetermined 0.000 - Uncertain Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1497 Loss 13 q12.11 chr13:19612306-19679872 67566 Inheritance - Paternal 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
DE35OSOUKBD100471 Gain 13 q14.11 chr13:43146433-43187994 41562 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE67OSOUKBD100477 Gain 13 q14.11 chr13:44032193-44171911 139719 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_0876 Loss 13 q12.3 chr13:29714684-29828112 113428 Inheritance - Paternal 0.000 - no comparable CNVs Benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1840 Loss 13 q31.1 chr13:85909019-86064348 155329 No parental DNA available 0.000 - Uncertain Benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
SKZ_1746 Loss 13 q21.31 chr13:64295459-64400173 104714 Inheritance - Paternal 0.000 - Uncertain- likely benign Benign Uncertain- likely benign Uncertain- likely benign Benign
SKZ_1976 Gain 13 q31.3 chr13:92958981-93035128 76147 Inheritance - Maternal 0.000 8 no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1746 Gain 13 q31.3 chr13:92979291-93049171 69880 Inheritance - Maternal 0.000 8 no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1662 Loss 13 q12.11 chr13:22688792-22981935 293143 Inheritance - de novo 0.000 - no comparable CNVs no comparable CNVs Benign Uncertain- likely benign Uncertain
DE91OSOUKBD100336 Gain 14 q11.2 chr14:21353205-21421877 68673 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE86OSOUKBD100232 Gain 14 q12 chr14:24947323-24986166 38844 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE92OSOUKBD100221 Loss 14 q21.2 chr14:44928342-45378475 450134 Inheritance - Undetermined 0.000 - Uncertain Uncertain Benign Uncertain- likely benign Benign
DE14OSOUKBD100461 Loss 15 q21.3 chr15:57711740-57749246 37507 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
DE44OSOUKBD100309 Gain 15 q26.3 chr15:102325461-102373183 47723 Inheritance - Undetermined 0.000 9 Uncertain- likely benign Uncertain- likely benign Benign Uncertain- likely benign Benign
DE76OSOUKBD100315 Gain 15 q26.3 chr15:102332446-102368280 35835 Inheritance - Undetermined 0.000 9 Uncertain- likely benign Uncertain- likely benign Benign Uncertain- likely benign Benign
SKZ_2032 Loss 15 q11.2 chr15:22665220-23147419 482199 Inheritance - not Maternal 0.000 - Uncertain Benign Benign Uncertain- likely benign Benign
SKZ_0845 Gain 15 q21.3 chr15:55354493-55956320 601827 Inheritance - Maternal 0.000 - Uncertain Uncertain no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1500 Loss 15 q24.2 - q24.3 chr15:76524284-76625437 101153 Inheritance - Maternal 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_0856 Loss 15 q13.3 chr15:32457092-32771537 314445 Inheritance - Paternal 0.000 - Uncertain- likely pathogenic Pathogenic no comparable CNVs Uncertain- likely benign Uncertain- likely pathogenic
DE62OSOUKBD100179 Gain 16 q12.1 - q12.2 chr16:52464934-52676323 211390 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1150 Gain 16 p13.11 chr16:15539023-16291541 752518 Inheritance - Paternal 0.000 10 Uncertain Uncertain Uncertain- likely benign Uncertain- likely benign Uncertain- likely pathogenic
SKZ_1988 Gain 16 p13.11 chr16:15034035-15998820 964785 Inheritance - Paternal 0.000 10 Uncertain Uncertain Uncertain- likely benign Uncertain- likely benign Uncertain- likely pathogenic
SKZ_1381 Gain 16 p13.2 chr16:7303708-7357294 53586 Inheritance - Paternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_0680 Loss 16 q23.2 chr16:81234781-81287239 52458 Inheritance - Maternal 0.000 - Uncertain- likely benign Benign Uncertain- likely benign Uncertain- likely benign Benign
DE45OSOUKBD100291 Loss 16 q24.1 chr16:84429584-84490643 61060 Inheritance - Undetermined 0.000 11 no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Benign
SKZ_1500 Loss 16 q24.1 chr16:84435058-84470476 35418 Inheritance - Maternal 0.000 11 no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
DE52OSOUKBD100262 Gain 16 q24.2 chr16:87738873-87812644 73772 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_2111 Gain 16 p13.11 chr16:14985615-17000304 2014689 Inheritance - de novo 0.000 10 Uncertain Uncertain- likely pathogenic Uncertain- likely benign Uncertain- likely benign Uncertain- likely pathogenic
DE08OSOUKBD100084 Loss 17 p11.2 chr17:17316541-17349835 33295 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign Benign Uncertain- likely benign Benign
SKZ_2032 Loss 17 p11.2 chr17:19417785-19579313 161528 Inheritance - not Maternal 0.000 - Benign Benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign
DE13OSOUKBD100285 Loss 17 p11.2 chr17:20051012-20592172 541161 Inheritance - Undetermined 0.000 - Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
DE89OSOUKBD100081 Loss 17 p13.2 chr17:3505638-3559746 54109 Inheritance - Undetermined 0.000 - Benign Benign no comparable CNVs Benign Benign
Internal Type Chr Cytoband Chromosome region HG19 Length Inheritance CNV-frequency cohort multiple ISCA DGV database web ClinGen CNV (likely) benign Control group developmental delay Authors classification
SKZ_1489 Gain 17 p13.3 chr17:735198-797669 62471 No parental DNA available 0.000 - no comparable CNVs Uncertain- likely benign Benign Uncertain- likely benign Benign
SKZ_1003 Loss 17 q11.2 chr17:25972552-26066964 94412 Inheritance - Maternal 0.000 - no comparable CNVs Uncertain no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1746 Gain 18 q11.2 chr18:22883781-23015036 131255 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign
SKZ_0369 Loss 18 q12.2 chr18:34546490-34698627 152137 Inheritance - Paternal 0.000 - Uncertain Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1130 Gain 19 q13.41 chr19:53647182-53693873 46691 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
DE61OSOUKBD100294 Loss 19 q13.42 chr19:55434213-55486661 52449 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
DE67OSOUKBD100477 Loss 20 p13 chr20:113651-184813 71163 Inheritance - Undetermined 0.000 - no comparable CNVs Benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_2032 Loss 20 p12.1 chr20:15062923-15103156 40233 Inheritance - Maternal 0.000 - Uncertain- likely benign Benign Benign Benign Benign
SKZ_1679 Loss 20 p13 chr20:3857650-3900324 42674 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
DE92OSOUKBD100221 Loss 20 p13 chr20:4931970-4972088 40119 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign Uncertain- likely benign
SKZ_1977 Loss 20 q11.23 chr20:36905828-36972896 67068 Inheritance - Maternal 0.000 - no comparable CNVs Benign Benign Uncertain- likely benign Benign
DE83OSOUKBD100480 Gain 21 q21.1 chr21:19622822-19810737 187916 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
DE02OSOUKBD100095 Gain 21 q22.12 chr21:37487858-37598197 110340 Inheritance - Undetermined 0.000 - Benign Uncertain- likely benign Benign Benign Benign
SKZ_1307 Gain 21 q22.2 chr21:40100880-40154748 53868 Inheritance - de novo 0.000 - no comparable CNVs Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign Uncertain- likely benign
SKZ_1825 Loss 22 q13.33 chr22:50645586-50949482 303896 Inheritance - not Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain
DE84OSOUKBD100074 Gain 22 q13.2 chr22:43090481-43161021 70541 Inheritance - Undetermined 0.000 - no comparable CNVs Uncertain- likely benign no comparable CNVs no comparable CNVs Uncertain- likely benign
DE37OSOUKBD100144 Loss 22 q12.1 chr22:26838242-26881031 42790 Inheritance - maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Uncertain- likely benign
SKZ_1780 Gain 22 q11.21 chr22:18637139-20289862 1652723 Inheritance - Maternal 0.000 - Pathogenic Pathogenic Uncertain- likely benign Uncertain- likely benign Uncertain- likely pathogenic
DE29OSOUKBD100191 Gain X q13.1 chrX:71537559-71609005 71447 Inheritance - Undetermined 0.000 - Uncertain- likely benign no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign
SKZ_1743 Gain X p22.31 chrX:8075662-8148705 73043 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign Benign no comparable CNVs Benign
DE86OSOUKBD100232 Gain X q28 chrX:154873222-155010594 137373 Inheritance - Undetermined 0.000 - no comparable CNVs no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign
DE46OSOUKBD100176 Gain X p22.2 chrX:13354873-13493086 138214 Inheritance - Undetermined 0.000 - Benign Uncertain- likely benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign
SKZ_2027 Gain X p22.33 chrX:1427577-1592679 165102 Inheritance - Maternal 0.000 - Uncertain- likely benign Uncertain Benign no comparable CNVs Uncertain- likely benign
SKZ_0374 Gain X p22.33 chrX:636950-820594 183644 Inheritance - Paternal 0.000 - Uncertain Uncertain Benign no comparable CNVs Uncertain- likely benign
SKZ_1508 Gain X p22.33 chrX:417624-636092 218468 Inheritance - Maternal 0.000 12 Uncertain Uncertain- likely benign Benign no comparable CNVs Uncertain- likely benign
DE94OSOUKBD100282 Gain X p22.33 chrX:370599-612414 241816 Inheritance - Undetermined 0.000 12 Uncertain Uncertain- likely benign Benign no comparable CNVs Uncertain- likely benign
SKZ_0887 Gain X p22.33 chrX:2059627-2314248 254621 Inheritance - Maternal 0.000 - Uncertain- likely benign Uncertain Uncertain- likely benign no comparable CNVs Uncertain- likely benign
DE27OSOUKBD100227 Gain X p22.31 chrX:8219053-8484026 264974 Inheritance - Undetermined 0.000 - Uncertain Uncertain- likely benign Benign no comparable CNVs Benign
SKZ_0680 Nullizygous X p22.2 chrX:10299643-10638042 338399 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs no comparable CNVs no comparable CNVs Pathogenic
SKZ_1855 Gain X q22.3 chrX:105098359-105625090 526731 No parental DNA available 0.000 - no comparable CNVs Uncertain- likely benign Uncertain- likely benign no comparable CNVs Uncertain- likely benign
SKZ_0887 Gain X q26.1 chrX:129681013-130305495 624482 Inheritance - Maternal 0.000 - no comparable CNVs no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign
SKZ_1932 Gain X p11.3 chrX:44073185-44716100 642915 Inheritance - Undetermined 0.000 - Uncertain no comparable CNVs Uncertain- likely benign no comparable CNVs Uncertain- likely benign
SKZ_0374 Gain X p22.33 chrX:426736-1215426 788690 Inheritance - Paternal 0.000 12 Uncertain Uncertain- likely benign Benign no comparable CNVs Uncertain- likely benign
Sample Cytoband CNV (Candidate) genes Phenotypes Validation procedure Classification
DE21OSOUKBD100141 2q21.1 hg19  chr2:g.(131349899_131486169)_(131991166_132057166)dup
Multiple incl. POTEJ, GPR148, AMER3, 
ARHGEF4, FAM168B, PLEKHB2 OA/TOF qPCR Uncertain-likely benign
DE12OSOUKBD100206 3p26.1 hg19  chr3:g.(8519329_8521841)_(8551649_8554052)dup LMCD1, LMCD1-AS1 OA/TOF, tracheomalacia qPCR Uncertain
SKZ_2111 7q35q36.3 hg19  chr7:g.(143820444_143839360)_(159119486_159138663)del Multiple incl. SHH, MNX1, SLC4A2 TOF, abnormally placed anus, hypospadias, ventricle septal defects FISH Pathogenic
SKZ_1810 
SKZ_1810
8p22 
11p14.3
hg19 chr8:g.(17613606_17625479)_(17613606 _17844353)dup
hg19 chr11:g.(21600567_21853276)_(22015682_22016670)del
FGL1, LFIRE1, MTUS1, PCM1 
-
OA/TOF, aplastic left  lung, Anencephaly, craniorachyschisis, kyphosis, ventricular septal defect, pulmonary 
stenosis, radial club hand, hypoplastic thumbs, horseshoe kidney, broad thorax
MAQ-assay 
MAQ-assay
Uncertain-likely benign 
Uncertain-likely benign 
SKZ_1662 13q12.11 hg19 chr13:g.(22685293_22688792)_(22978753_22981935)del AK054845, LINC00540 OA/TOF, tracheal stenosis, abnormal sacrum and kidney abnormality MAQ-assay Uncertain
SKZ_2111 16p13.11 hg19 chr16:g.(14985615_15156180)_(16289532_17000304)dup Multiple TOF, abnormally placed anus, hypospadias, ventricle septal defects MAQ-assay Uncertain-likely pathogenic
SKZ_1307 21q22.2 hg19 chr21:g.(40099972_40100880)_(40152372_40154748)dup LINC00114 OA/TOF, anal stenosis and long toes and fingers MAQ-assay Uncertain-likely benign
Cytoband CNV
minimum 
Length (bp) (Candidate) genes Phenotypes Reference
1q41
hg19 chr1:g.(?_217879151)_(218010441_?)dup
hg19 chr8:g.(?_144940222)_(145060112_?)dup
131290 
119890
SPATA17 
PLEC-1, PARP10
OA, butterfly vertebra, anal atresia without fistula, atrial and ventricular septal defects, 
bilateral dystopic kidneys, left-sided renal dysplasia 21
2q33.2q35 hg19 chr2:g.(?_204,394,564)–(219,189,331_?)del 14794767 MAP2
OA, agenesis of umbilical artery, multiple brain abnormalities, tapered fingers , 
clinodactyly of the fifth fingers, deviated feet 22
3q28 hg19 chr3:g.(?_187913191)_(188468682_?)del 555491 LPP OA/TOF, Tetralogy of Fallot, rib anomalies, hypospadias, small kidneys 23
7q35q36 hg19 chr7:g.(?_147683847)_(159088636_?)del 11404789 SHH, MNX1
oesophageal stenosis, microcephaly, facial dysmoprphism hypoplasia of the lower lumbar vertebrae,
 lumbosacral hyperlordosis, partial agenesis of sacrum, distended bladder, right ectopic kidney, 
developmental delay 24,25
11q13.1q13.2 hg19 chr11:g.(?_65508902)_(67473140_?)del 1964238 GSTP1 OA, facial dysmorphism, developmental delay 26
17q12 hg19 chr17:g.(?_34727386)_(36297053_?)dup 1569667 AATF, TADA2L, HNF1B OA/TOF, anal atresia, sacral bone defect, cryptorchidism 27
20q13.33 hg19 chr20:g.(?_60238426)_(60895697_?)del 657271 GTPBP5 OA/TOF, ventricular septal defects, hypospadias, large unilateral hydrocele, large left cystic hygroma 28
Sample Cytoband CNV Inheritance Authors classification Phenotype
DE61OSOUKBD100197 2q13 hg19 chr2:g.(111186302_111667198)_(113094793_113273657)dup U Uncertain- likely pathogenic OA/TOF , sister as unilateral renal agenesis, both patient and sister are otherwise healthy
SKZ_1248 4q35.2 hg19 chr4:g.(187540292_187318091)_(187318091_187849681)dup M Uncertain- likely pathogenic OA/TOF, pyloric stenosis; dysmorphisms, hearing loss
SKZ_1856 6p22.3 hg19 chr6:g.(20884837_20901311)_(20901267_21082258)del NP Uncertain- likely pathogenic OA/TOF, septal defect, club foot
SKZ_1855 11p15.4 hg19 chr11:g.(4371631_4391231)_(5132119_5253127)dup NP Uncertain- likely pathogenic OA/TOF
SKZ_0856 15q13.3 hg19 chr15:g.(32457092_32457092)_(32514341_32771537)del P Uncertain- likely pathogenic OA/TOF, Anal atresia, bifid/fused ribs, coarctation, abnormal arterial supply right lung, abnormal sacrum
SKZ_1150 16p13.11 hg19 chr16:g.(15539023_15545022)_(16282307_16291541)dup P Uncertain- likely pathogenic OA/TOF + Atrio-ventricular septal defect
SKZ_1988 16p13.11 hg19 chr16:g.(15034035_15092778)_(15998820_16106095)dup P Uncertain- likely pathogenic OA/TOF, anal anomalies
SKZ_1780 22q11.21 hg19 chr22:g.(18637139_18640300)_(20286099_20289862)dup M Uncertain- likely pathogenic OA/TOF, Anal atresia, ventricular septal defect
SKZ_0680 Xp22.2 hg19 chrX:g.(10299643_10302384)_(10637327_10638042)del M Pathogenic Laryngo-tracheo-oesophageal-cleft, hypospadias, dysmorphims, hypotonia, pyloric stenosis; Opitz syndrome
